{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2","upperLimit":"2.7","value":"2.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"146"}],"units":"Participants"}],"description":"PFS was defined as the time from administration of the first dose to the first documented disease progression according to RECIST v1.1 or death due to any cause, whichever occurs first. Patients who were alive and had not experienced disease progression at the time of data cutoff were censored.","dispersionType":"95% Confidence Interval","groups":[{"description":"MK-3475: 200 mg of MK-3475 administered intravenously on Day 1 of every 21-day cycle","id":"OG000","title":"All Patients Who Received at Least One Dose of the Drug"}],"paramType":"MEDIAN","populationDescription":"All patients who have received at least 1 dose of study medication with at least one adequate on-study tumor assessment were included in the efficacy analysis. If a patient discontinued the study before the first radiological assessment due to progression of disease, either radiological or clinical, they were considered evaluable and were included in the efficacy analysis. One patient enrolled in the ACC cohort was excluded from the study due to change in the diagnosis.","reportingStatus":"POSTED","timeFrame":"Baseline and every 9 weeks thereafter. After 6 months, every 12 weeks at the physician's discretion, if patient has had CR, PR, or SD > 27 weeks, an average of 4 years.","title":"Progression-free Survival (PFS) Using RECIST v1.1","type":"SECONDARY","unitOfMeasure":"months"}